Main features of Augmentin 400mg/57ml
Augmentin 400mg/57ml is a pharmaceutical product which combines 2 main components: amoxicillin and clavulanic acid. The final product is an antibiotic which is resistant to a wide variety of microorganisms which develop infections within the body.
Amoxicillin derives from penicillin family of antibiotics. Relying on the fact that penicillins have developed susceptibility to certain pathogenic strains and microorganisms, clavulanic acid is added into Augmentin 400mg/57ml composition. Its role consists in preventing amoxicillin to become susceptible to bacterial action. Clavulanic acid is a beta-lactamase inhibitor, which means that it prevents beta-lactamase enzymes to degrade antibiotic action.
What does Augmentin 400mg/57ml treat?
This antibiotic is efficient for the treatment of a large variety of bacterial infections. It is essential to mention the fact that Augmentin 400mg/57ml will furnish high effectiveness only in health conditions which are triggered by susceptible bacteria. In this context, culture investigations should be performed before initiating Augmentin 400mg/57ml therapy. In the absence of these findings, patients are likely to develop bacterial resistance with this drug, when administered without susceptibility confirmation.
Laboratory studies show that Augmentin 400mg/57ml is potent against Staphylococcus Aureus, Escherichia Coli, Klebsiella, Enterococcus faecalis, Streptococcus pneumoniae, Neisseria gonorrhoeae, Streptococcus pyogenes, Staphylococcus epidermidis, Proteus mirabilis, etc…
As it can be deduced, Augmentin 400mg/57ml is able to treat any infection caused by mentioned pathogenic agents. These include: lower respiratory tract infections, pyelonephritis, dermatological infections, otitis media, sinusitis, urinary tract infections.
Which threats are related to Augmentin 400mg/57ml therapy?
Penicillin medications, including Augmentin 400mg/57ml, might occasionally produce hypersensitive reaction. The allergic reaction manifests in severe form and can include anaphylactic shock. A profound inquiry about previous allergic responses should be performed before indicating this medication. Statistics show that such reaction is predominant (but not exclusive) in persons who have previously developed allergic reaction to cephalosporin group of drugs. In case that such history is present, patients should not take the risk.
Patients receiving antibiotics are prone to develop pseudo-membranous colitis. While intestinal flora is altered due to antibiotic activity, Clostridium difficile is probable to overgrow. This bacterium secretes certain toxins which are extremely harmful. Toxins affect the flora, leading to abnormal diarrhea and electrolyte imbalance. The phenomenon can develop to high degrees of severity, posing an eminent threat to patient’s life. Gastrointestinal colitis and diarrhea are syndromes which might predict the emerge of Clostridium Difficile-associated diarrhea. If the diagnose is confirmed, Augmentin 400mg/57ml administration will de interrupted, and appropriate measures against the infection will be provided.
Augmentin 400mg/57ml administration during pregnancy
Augmentin 400mg/57ml antibacterial drug should be taken by pregnant women only in cases of major need for the mother, and when there are no safer alternatives available. The drug has not manifested toxic effects when observed in animal tests. However, findings based on animal studies cannot guarantee total safeness when Augmentin 400mg/57ml is taken by pregnant women.
Possible side events
In terms of tolerability, Augmentin 400mg/57ml has a rather positive profile. Watery stools are experienced by 7-9% of receivers. Nausea and vomiting affects less than 5% of users (3 and 1%, respectively). Skin affections (urticaria, for instance) are observed in 3% of patients.